ライフサイエンスコーパス: blind study

1 Alsace) is a prospective, randomized, double-blind study.

2 f acute inflammation) or placebo in a double-blind study.

3 12 months in a phase II, multicentre, double-blind study.

4 with MTX (placebo group), in a 2-year double-blind study.

5 nazine, with several newer drugs in a double-blind study.

6 endectomy in a prospective randomized double blind study.

7 ceive colchicine or methotrexate in a double-blind study.

8 28 mm) in a prospective, randomized, double-blind study.

9 This was a multicenter, randomized, double-blind study.

10 led in this prospective, multicentre, double-blind study.

11 e month off of hormone treatment in a double-blind study.

12 erapy after 1 month off therapy, in a double-blind study.

13 rospectively in a larger, randomized, double-blind study.

14 ate or polysaccharide vaccine in an observer-blind study.

15 This algorithm is illustrated using a blind study.

16 is were included in this prospective, double-blind study.

17 (n=83) for 24 weeks in a randomized, double-blind study.

18 in a placebo-controlled, randomized, double-blind study.

19 se 2, randomized, placebo-controlled, double-blind study.

20 bo (n=15) for 14 days in a randomized double-blind study.

21 IV metastasis tissue microarrays in a double-blind study.

22 sitive and negative samples through a double-blind study.

23 centration range spanning 25-150ng/microl in blind studies.

24 environmental isolates were broken up into 2 blind studies.

25 Randomized, placebo-controlled, double-blinded study.

26 ted to pyrosequencing analysis in a strictly blinded study.

27 original panel used to score isolates in the blinded study.

28 will never be settled without a prospective blinded study.

29 se chain reaction (PCR) assay in an operator-blinded study.

30 n demonstrated in a prospective, randomized, blinded study.

31 ibility of this technique was validated in a blinded study.

32 g daily or tamoxifen 20 mg daily in a double-blinded study.

33 ") was investigated in a phase 1 randomized, blinded study.

34 Of 3,964 patients in double-blind studies, 1,427 had a history of atrial fibrillatio

35 this 24-week multicenter, randomized, double-blind study, 1,220 type IIa or IIb hyperlipidemic patien

36 ODS AND In a multicenter, randomized, double-blind study, 123 patients with stable coronary artery di

37 In this phase 2, double-blind study, 124 subjects with biopsy-proven NASH were r

38 In this double-blind study, 127 patients with psoriatic arthritis (PsA)

39 In a double-blind study, 148 clinically stable, overweight (body mas

40 In a randomized, double-blind study, 17 healthy human subjects received on 4 sep

41 In this double-blind study, 17 HIV-infected individuals with viral load

42 In this double-blind study, 1797 patients with hypertension (mean sitti

43 In a blind study, 18 samples enriched with one or more inhibi

44 In the double-blind study, 20 of the 29 patients in the recombinant al

45 In the double-blind study, 21 of the 26 patients who received placebo

46 mized, flexible-dose, parallel-group, double-blind study, 280 men with erectile dysfunction for at le

47 In this randomized double-blind study, 399 students either wrote about their most

48 In this 4-week double-blind study, 404 patients were randomized to 20 mg/d (n

49 In a prospective, single-center, single-blind study, 44 (of 139 screened, 31.7%) ACS patients wi

50 In this randomized, investigator-blinded study, 50 patients underwent oral preparation wi

51 In a parallel-group, double-blind study, 52 (14 men, 38 women) healthy normal-weight

52 In a prospective, single-center, single-blind study, 55 out of 117 (47%) screened consecutive ST

53 dies included 1 randomized clinical observer-blinded study (6 patients), 4 nonrandomized clinical tri

54 In this multicenter, double-blind study, 615 patients with first-ever unprovoked ven

55 In a double-blind study, 628 patients with baseline LDL-C 145 to 250

56 In this 24-week, double-blind study, 672 patients underwent randomization and 65

57 e fluoxetine or placebo in a 12-week, double-blind study; 73% (59 of 81) of the patients in each trea

58 In a double-blind study, 80 depressed patients were randomized to RU

59 In this double-blind study, 87 immunocompromised patients with clinical

60 In a blind study, a panel of 20 DNA samples was prepared from

61 In this double-blind study, adult patients with hyperuricemia and gout

62 In a multicenter, double-blind study, adults (ages 18-64 years) with treatment-re

63 In this randomized, double-blind study, adults with HDM-associated allergic rhiniti

64 olved, since results of the SGS-PCR and SASG blinded study agreed with each other and confirmed the S

65 In a 3 d double-blind study and in a 10 d repeated stimulation study, bi

66 Patient samples were analyzed in a blind study and results concurred with their diabetes mu

67 responded to treatment then entered a double-blind study and were randomly assigned to receive either

68 prove the estimation of treatment effects in blinded studies and, most importantly, opens the doors t

69 ts who were enrolled, 400 entered the double-blind study, and 370 received at least one postbaseline

70 or nonrandomized, open-label randomized, and blinded studies; and (2) quantification of 3 biases pote

71 Randomized, blinded studies are underway to confirm these observatio

72 This prospective, blinded study assessed oral washes as a more convenient

73 /3, randomized, placebo-controlled, observer-blinded study assessed the immunogenicity, reactogenicit

74 akinra (100 mg/day) for 6 months in a double-blind study at 41 centers in the US.

75 We performed a double-blind study at 49 hospitals in Europe and Israel, compri

76 performed a prospective, randomized, double-blind study at 5 level 1 trauma centers.

77 This 12-month double-blind study attempted remission induction using standard

78 We tested these hypotheses in a blind study by nebulizing 7- to 14-d-old macaques (n = 2

79 In this double-blind study children with PA were randomized to receive

80 In a double-blind study, children and adolescents with ADHD (N=171,

81 n a prospective, randomized, controlled, and blinded study, children undergoing SPT were or were not

82 This 47-week, randomized, double-blind study compared flexibly dosed olanzapine (5-20 mg/

83 This multicenter, randomized, double-blind study compared mibefradil with placebo as adjunct

84 This randomized, double-blind study compared olanzapine, quetiapine, risperidone

85 This double-blind study compared the effect of palifermin with that

86 This randomized double-blind study compared the efficacy and safety of intraven

87 ed, placebo-controlled, double-dummy, double-blind study compared the magnitude and duration of analg

88 t 2015, this randomized, prospective, single-blinded study compared 2 groups (a TAP block and PILA) w

89 A randomized double-blind study comparing aprepitant versus dexamethasone wa

90 nts were enrolled in this randomized, double-blind study comparing losartan (50 to 100 mg once daily)

91 A prospective single-center, examiner-blind study comparing the effects of a staggered prophyl

92 al fistulas were prospectively enrolled in a blinded study comparing EUS, MRI, and examination under

93 Here we report the results of a blinded study comparing the in vitro canine atrial elect

94 THODS We conducted a randomized, controlled, blinded study comparing true acupuncture (TA) versus sha

95 This prospective, blinded study comprised 703 asymptomatic persons at high

96 A 6-week, randomized, double-blind study conducted between February 2013 and May 2015

97 AND PATIENTS: Randomized, controlled, single-blind study conducted between January 2, 2006, and Janua

98 X-ACT was a phase III, randomized, double-blind study conducted in 24 centres (Germany), which sel

99 PATIENTS: Single-center, randomized, double-blind study conducted in a level 3 pediatric intensive c

100 In a double-blind study conducted in the winter, 30 healthy male sub

101 In this prospective, multicenter, blinded study conducted at 35 international centers, we

102 ion in a randomized, crossover, investigator-blinded study conducted in an emergency department and t

103 than 90% correct identification rate for the blind study data, suggesting that this approach has the

104 nment bias, and only 2 studies with a double-blinded study design have been conducted.

105 olves randomized, placebo-controlled, double-blind studies designed to maximize statistical power.

106 multicenter, prospective, randomized, single-blinded study designed to demonstrate a reduction in sym

107 In this randomised, double-blind study, done at 87 sites in 13 countries, we recrui

108 ups who received at least one dose of double-blind study drug.

109 rm; if not, open-label MA 20 mg was added to blinded study drug and continued for 3 months.

110 Of the 13,642 patients taking the blinded study drug at the end of the trial, 9,304 (68.2%

111 All patients on the blinded study drug at the trial's conclusion were includ

112 en PCI was carried out in patients receiving blinded study drug during PCI (n = 2,178).

113 spitalization or UFH for at least 48 h, with blinded study drug to continue if PCI was performed.

114 711 patients were enrolled, and 702 received blinded study drug.

115 articipating in a 12-week multicenter double-blind study during which they received placebo or one of

116 In this randomized, single-blinded study, EECP improved exercise tolerance, quality

117 In this randomised, double-blind study eligible patients were aged 36-70 years, had

118 In this phase 3 double-blind study, eligible participants were children with im

119 lled in this prospective, randomized, single-blind study, employing a split-scalp design, comparing t

120 The primary double-blind study end points were changes between baseline and

121 This prospective, blinded study enrolled 46 patients who were undergoing m

122 enty-nine of the 89 patients in the original blinded study enrolled in the extension study, and 65 of

123 nter, randomized, placebo-controlled, double-blind study evaluated the efficacy and safety of cinacal

124 This randomized, placebo-controlled, double-blind study evaluated the efficacy and safety of palifer

125 mo were enrolled in this randomized, single-blinded study for 9 mo, designed primarily to assess inc

126 ospective, single-center, randomized, single-blinded study from July 2009 through February 2011, eval

127 Published data in a placebo-control blinded study, however, are needed.

128 conducted a multicenter, randomized, double-blind study in 394 healthy adults.

129 d an inactivated H7N9 vaccine in an observer-blind study in healthy adults aged 18-64 years.

130 conducted a prospective, randomized, double-blind study in healthy, preterm infants (gestational age

131 id Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =

132 ter, prospective, placebo-controlled, double-blind study in which 564 high-risk patients undergoing c

133 We conducted a randomized, double-blind study in which 87 patients between 8 and 40 years

134 We conducted a double-blind study in which previously untreated adults with HC

135 mance of the standard operating procedure in blinded studies in five independent laboratories.

136 rs, a placebo controlled, randomized, double blinded study in active steroid dependent and steroid re

137 and normal control subjects in a randomized blinded study in the U.S. and U.K.

138 Subsequently, 2 platforms were used in a blinded study in which a heterogeneous collection of 196

139 esults of a multinational randomized, double-blind study, in which postmenopausal women with osteopor

140 BITION was a multicentre, randomised, double-blind study, in which treatment-naive patients with pulm

141 prospective, multicenter, randomized, double-blind study included 397 patients who were randomized on

142 In randomized, double-blind studies, infiltration of the neurovascular bundles

143 In a 6-week double-blind study, inpatients with a recent exacerbation of sc

144 Occluder to Medical Management) was a double-blind study investigating migraine characteristics over

145 This was a double-blind study investigating the effects of three doses of

146 This randomized, double-blind study involved three antiretroviral regimens for t

147 In this randomized, double-blind study involving 10 days of treatment and 30 days o

148 In this double-blind study involving 142 patients with metastatic melan

149 ternational, multicenter, randomized, double-blind study involving 1862 patients with ongoing STEMI o

150 ion studies [PS]) were evaluated in a double-blind study involving 284 methicillin-resistant Staphylo

151 year, placebo-controlled, randomized, double-blind study involving 87 elderly men with low levels of

152 fic T cell responses were characterized in a blinded study involving infected individuals and their s

153 lind placebo on day -1 (baseline) and double-blind study medication (placebo [n = 12] or lixivaptan 1

154 nts who received at least one dose of double-blind study medication and who had both a baseline and a

155 Blinded study medication dose was uptitrated to 15 mg or

156 In 2 phase III, randomized, double-blind studies, men and women with HIV-associated abdomin

157 In a randomized double-blind study (n = 127), science faculty from research-int

158 itiative study in 2002, a prospective double-blind study, noted an increased risk of breast cancer if

159 In a double-blind study, nucleos(t)ide-naive patients with high leve

160 view and meta-analysis of randomised, double-blind studies of oral and topical pharmacotherapy for ne

161 A blind study of 11 clinical isolates was performed, and e

162 zed, prospective, placebo-controlled, double-blind study of 122 patients at 17 centers in Europe and

163 In a randomized placebo-controlled double-blind study of 162 HIV-negative RV144 vaccine recipients

164 We performed a double-blind study of 165 patients with primary biliary cirrhos

165 In a blind study of 24 clinical sputum samples, resistance mu

166 In a double-blind study of 40 patients with malignant melanoma who w

167 nter, randomized, placebo-controlled, double-blind study of 58 patients who were treated every 2 week

168 were entered into a parallel design, single-blind study of 6 months' duration.

169 A double-blind study of 672 patients with OA of the knee was cond

170 In a blind study of 72 influenza virus isolates, RNA from a w

171 e performed a multi-center, parallel, single-blind study of 75 patients who met Rome III criteria for

172 COU-AA-301 is a randomized, double-blind study of AA (1,000 mg every day) plus P (5 mg by m

173 performed a randomized placebo-phase, double-blind study of alirocumab 150 mg administered subcutaneo

174 this randomized, placebo-controlled, double-blind study of AZ 100 mg on all-cause mortality.

175 this randomized, placebo-controlled, double-blind study of azimilide 100 mg on all-cause mortality.

176 ducted an 8-week, placebo-controlled, double-blind study of E-EPA in 30 female subjects meeting Revis

177 Data were obtained from a randomized, double-blind study of patients with moderate-to-severe fibromya

178 Randomized, double-blind study of patients with schizophrenia assigned to r

179 lerant Subjects) trial was a 12-week, double-blind study of randomized patients (2:2:1:1) to evolocum

180 e disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol.

181 ontrolled, dose-response, randomized, double-blind study of the effect of vitamin D on calcium absorp

182 orted a protective effect on diarrhoea while blinded studies of household water treatment in low-inco

183 ever, our findings are consistent with other blinded studies of similar interventions and raise addit

184 , recent systematic reviews and results from blinded studies of water quality interventions have rais

185 Furthermore, in a randomized, blinded study of 176 rats with myocardial infarction, na

186 This prospective, multicenter, single-blinded study of 232 patients (age 53 +/- 10 years, 186

187 ents II) trial was a single-center, assessor-blinded study of 240 patients randomly assigned in a 1:1

188 Phase 2 randomized, controlled, double-blinded study of 4 antiretroviral regimens used as PrEP.

189 ta deposition and tau phosphorylation in the blinded study of APP/PS1 transgenic mice treated intrape

190 tial diagnostic utility, we then performed a blinded study of bronchoalveolar lavage (BAL) fluid spec

191 s) that participated in a randomized, double-blinded study of intracoronary RT completed a questionna

192 rformed a randomized, multicenter, partially blinded study of patients (23 with HCV genotype 2, 26 wi

193 roof of principle was established in a large blinded study of phase-known samples.

194 Blinded studies on sera from postmenopausal patients wit

195 In a Phase II double-blind study, orally administered interferon alpha (150 U

196 owever, it can be difficult or impossible to blind study participants and unblinded trials are common

197 f a phase 3, randomised, multicentre, double-blind study, patients aged 6 months to 17 years with a d

198 In a large placebo-controlled, double-blind study, patients ages 6-16 with ADHD, any subtype,

199 In a double-blind study, patients received placebo or a probiotic co

200 In this double-blind study, patients with DSM-IV generalized anxiety di

201 multicenter, investigator-initiated, double-blind study, patients with first-ever unprovoked venous

202 In this double-blind study, patients with type 2 diabetes (either drug-

203 In a single-blind study performed at 2 referral centers we assigned

204 cultures similar to that done for an initial blind study previously reported.

205 This 6-month, double-blind study randomized patients with moderate to severe

206 This 3-week, multicenter, double-blind study randomly assigned 262 bipolar disorder patie

207 In a randomized, double-blind study, sildenafil 100 mg or placebo was given oral

208 otypic determination of RMP resistance in a "blind study." Similarly, PZA resistance was determined u

209 In two identical phase 3, double-blind studies (study 04, 652 participants; study 05, 700

210 mized, placebo-controlled, crossover, single-blinded study (subject) placebo once and 3.0 pmol/kg/min

211 This randomized, double-blind study tested the hypothesis that rofecoxib, a drug

212 rtery lesions) trial is a randomized, double-blind study that compared sirolimus-eluting and bare met

213 were part of the URICO-ICTUS trial, a double-blind study that compared the administration of uric aci

214 bsequently used to identify 53 unknowns in a blind study that included 39 human patient samples and 1

215 Phase 2 was a double-blind study that randomly assigned patients (1:1:1) usin

216 We quantitatively validate the method via a blind study that seeks to identify microorganisms with k

217 Our aim was to compare in a prospective blinded study the cognitive and mood effects of subthala

218 In blind studies, the five miRNA PCa biomarkers were able t

219 In a placebo-controlled, double-blind study, the authors investigated the efficacy and s

220 In a randomized, double-blind study, the efficacy of scorpion-specific F(ab')(2)

221 In a blinded study, the signature algorithm showed independen

222 In the double-blind study, there were no significant differences betwe

223 ndomized, controlled, patient- and evaluator-blinded study (Tissucol/Tisseel for MEsh fixation in LIc

224 ed a multicenter, placebo-controlled, double-blind study to confirm these results in cardiac-transpla

225 In total, 52 methods were used in the single-blind study to determine method accuracy and comparabili

226 performed a prospective, randomized, double-blind study to determine whether calcium and calcitriol

227 We performed a crossover, randomized, double-blind study to evaluate HT bioavailability in HT-enriche

228 procedure, we performed a randomized, double-blind study to evaluate the impact of an incision in the

229 severe disease, randomized in a 13-wk double-blind study to placebo (n = 73) or salmeterol/fluticason

230 rculation were randomly assigned in a double-blind study to receive high-dose aprotinin, epsilon-amin

231 des-infected subjects randomized in a double-blind study to receive two doses of either albendazole o

232 MChip assay) for influenza was compared in a blind study to that of viral culture, reverse transcript

233 We performed a blinded study to compare repetitive-sequence PCR and mul

234 A randomized double-blinded study to define the activity of IM862 in patient

235 We performed a prospective, single-blinded study to explore the reliability of body surface

236 or patients compliant to therapy (ie, taking blinded study treatment >/=80% of the time) compared wit

237 We undertook a double-blind study using stereological cell counting methods to

238 Blinded studies using the assay to identify the bacteria

239 Nonrandomized, single-blinded study using an interrupted time-series design.

240 Here, in a double-blinded study using objective spatiotemporal gait analys

241 sophageal candidiasis was tested in a double-blind study versus oral fluconazole.

242 Women, selected at the final blinded study visit 4 years after vaccination, provided

243 All women who attended the final blinded study visit and consented to anal specimen colle

244 ospective, single-center, randomized, double-blind study was conducted at the Brazilian Center for St

245 A phase III, randomized, double-blind study was conducted by the North Central Cancer Tr

246 This randomized, double-blind study was conducted in 142 sites in 17 countries.

247 A randomized, placebo-controlled, double-blind study was conducted in healthy adults aged 18-84 y

248 A randomized, crossover, double-blind study was conducted in healthy and MetS adults (n

249 A blind study was conducted on a well-characterized panel

250 A randomized, double-blind study was conducted to assess the anti-HIV and ant

251 A multicenter, double-blind study was conducted to determine rates of symptoma

252 A randomized, double-blind study was conducted to evaluate the pharmacokineti

253 An 8-week double-blind study was conducted with 28 patients who were diag

254 A 12-week, randomized, double-blind study was designed to compare gabapentin (1,200-2,

255 A controlled, single-blind study was designed to measure the effect of ibupro

256 A prospective double-blind study was performed comparing VHC to vancomycin an

257 he aim of this prospective randomized double-blind study was to compare the efficacy and safety of bo

258 The purpose of this double-blind study was to evaluate the efficacy of the LDS and

259 This randomised, double-blind study was undertaken in 117 sites in North and Sou

260 tive, randomized, placebo-controlled, double-blinded study was performed in 6 academic medical center

261 Recently, a prospective, double-blinded study was performed to help settle the debate.

262 In a multicenter randomized double-blind study we demonstrated that Qiliqiangxin (QLQX), a

263 In two multisite, randomized, double-blind studies, we compared a single application of 0.5%

264 In blind studies, we could not distinguish between the effe

265 In four multicenter, randomized, double-blind studies, we randomly assigned patients with actini

266 nter, randomized, placebo-controlled, double-blind study, we assign 597 subjects with psoriasis to re

267 In this randomized, double-blind study, we assigned 14,671 patients to add either s

268 In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg tw

269 In this randomized, double-blind study, we compared the effect of 6 months of simva

270 In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg a

271 this randomised, placebo-controlled, double-blind study, we enrolled adults (aged 18-80 years) at le

272 this randomised, placebo-controlled, double-blind study, we enrolled patients aged 18 years or older

273 nter, randomized, placebo-controlled, double-blind study, we evaluated alefacept as a treatment for p

274 In a double-blind study, we evaluated subjects with the amnestic sub

275 his phase 3, multicenter, randomized, double-blind study, we evaluated the efficacy and safety of oma

276 In a double-blind study, we randomly assigned 1049 consecutive patie

277 In this double-blind study, we randomly assigned 1088 patients to recei

278 In this double-blind study, we randomly assigned 2392 young women (defi

279 In a placebo-controlled, double-blind study, we randomly assigned 32 healthy volunteers

280 In this phase 3, double-blind study, we randomly assigned 443 patients with symp

281 In a substudy of a larger double-blind study, we randomly assigned 602 healthy men who ha

282 rst year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1:1:1 ra

283 In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, par

284 In a blinded study, we analyzed 57 thin-layer slides that had

285 In an open-label blinded study, we compared intracoronary and transendoca

286 In this blinded study, we confirmed the utility of CRISPR-MVLST

287 In this multinational, phase 3, observer-blinded study, we randomly assigned children 3 to 8 year

288 In a prospective, randomized, observer-blinded study, we treated 60 dyslipidemic subjects witho

289 est, a set of unknown metal ion solutions in blind studies were also successfully identified based on

290 d, 6 randomized open-label, and 2 randomized blinded studies were analyzed for 2 outcomes: (1) blood

291 In a randomized, blinded study, wild-type (WT) and Cln3(Deltaex7/8) mice

292 Double-blind studies with sufficient power to resolve this issu

293 x 2, randomized, placebo-controlled, double-blind study with 3 active treatments: folic acid (2.5 mg

294 In this double-blind study with a 2-by-2 factorial design, we randomly

295 In a blinded study with 182 longitudinal samples from infants

296 A blinded study with 200 HCV-infected samples was 97% accu

297 The assay was evaluated in a blinded study with 322 coded samples that included genom

298 In a blinded study with post-mortem brain tissue from patient

299 multicenter prospective randomized observer-blinded study with two parallel groups.

300 uting Stent Below the Knee-Randomised Double-Blind Study [YUKON-BTX]; NCT00664963).